Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZIMMER BIOMET HOLDINGS, INC.

(ZBH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/15/2021 06/16/2021 06/17/2021 06/18/2021 06/21/2021 Date
158.34(c) 158.03(c) 160.39(c) 158.51(c) 163.48 Last
1 376 843 1 426 162 1 367 058 2 238 958 1 580 142 Volume
+0.50% -0.20% +1.49% -1.17% +3.14% Change
More quotes
Financials (USD)
Sales 2021 8 125 M - -
Net income 2021 1 063 M - -
Net Debt 2021 6 215 M - -
P/E ratio 2021 31,2x
Yield 2021 0,60%
Sales 2022 8 526 M - -
Net income 2022 1 314 M - -
Net Debt 2022 4 641 M - -
P/E ratio 2022 25,4x
Yield 2022 0,63%
Capitalization 34 083 M 34 083 M -
EV / Sales 2021 4,96x
EV / Sales 2022 4,54x
Nbr of Employees 20 000
Free-Float 66,7%
More Financials
Company
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones,... 
More about the company
Ratings of Zimmer Biomet Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ZIMMER BIOMET HOLDINGS, INC.
06/15BACTIGUARDá : coated Zimmer Biomet trauma implants for infection prevention laun..
AQ
06/07Zimmer Biomet Holdings Names Chief Science, Technology and Innovation Officer
MT
05/25ZIMMER BIOMETá : Barclays Starts Zimmer Biomet Holdings at Overweight With $210 ..
MT
05/20ZIMMER BIOMET HOLDINGS, INC.á : Change in Directors or Principal Officers, Amend..
AQ
05/19ZIMMER BIOMETá : to Present at Bernstein's 37th Annual Strategic Decisions Confe..
PR
05/11ZIMMER BIOMETá : JMP Securities Adjusts Price Target on Zimmer Biomet Holdings t..
MT
05/05ZIMMER BIOMETá : Oppenheimer Adjusts Zimmer Biomet Holdings PT to $195 From $185..
MT
05/05ZIMMER BIOMETá : UBS Adjusts Price Target on Zimmer Biomet Holdings to $195 From..
MT
05/05ZIMMER BIOMETá : Morgan Stanley Adjusts Price Target for Zimmer Biomet to $195 F..
MT
05/05ZIMMER BIOMETá : JPMorgan Adjusts Price Target for Zimmer Biomet Holdings to $17..
MT
05/05ZIMMER BIOMETá : SVB Leerink Adjusts Zimmer Biomet Holdings PT to $205 From $200..
MT
05/05ZIMMER BIOMETá : Raymond James Adjusts Price Target on Zimmer Biomet Holdings to..
MT
05/04ZIMMER BIOMETá : Management's Discussion and Analysis of Financial Condition and..
AQ
05/04ZIMMER BIOMETá : Needham Adjusts Price Target for Zimmer Biomet Holdings to $202..
MT
05/04ZIMMER BIOMETá : 2020 and 2019
PU
More news
News in other languages on ZIMMER BIOMET HOLDINGS, INC.
2020Medicrea n’échappe pas au destin américain des medtech françaises
2020MEDARTIS : nouvelle responsable pour la région Emea
2020Medartis ernennt Mareike Loch zur Vice President EMEA
2020IMPLANETá : nomination d'un responsable pour l'Allemagne
2019La centrale nucléaire américaine de Three Mile Island arrêtée définitivement
More news
Analyst Recommendations on ZIMMER BIOMET HOLDINGS, INC.
More recommendations
Chart ZIMMER BIOMET HOLDINGS, INC.
Duration : Period :
Zimmer Biomet Holdings, Inc. Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Average target price 190,82 $
Last Close Price 158,51 $
Spread / Highest target 32,5%
Spread / Average Target 20,4%
Spread / Lowest Target -15,5%
EPS Revisions
Managers and Directors
NameTitle
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Nitin Goyal Chief Science, Technology & Innovation Officer
Ivan Tornos Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS, INC.2.87%33 046
ABBOTT LABORATORIES0.77%196 037
MEDTRONIC PLC5.20%165 794
BECTON, DICKINSON AND COMPANY-3.87%69 953
HOYA CORPORATION1.26%48 451
ALIGN TECHNOLOGY, INC.12.59%47 612